Generalized Bullous Eruption after Routine Vaccination in a Child with Diffuse Cutaneous Mastocytosis

Bankova, Lora G.; Walter, Jolán E.; Iyengar, Shuba R.; Lorenzo, Mayra E.; Hornick, Jason L.; Castells, Mariana

doi:10.1016/j.jaip.2012.08.008

Cited by 33 publications

(44 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with DCM are particularly prone to MC triggers due to skin manipulation, as perivascular MC infiltrates are present even in areas of skin that appear normal on the surface . Even precipitous temperature changes and routine vaccination can cause severe generalized blistering . Therefore, patients are likely to suffer severe reactions in response to MC triggers ubiquitous in daily life unless they are educated regarding conscious avoidance of MC triggers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis

Otani

Carroll

Yager

et al. 2018

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…3,16 Even precipitous temperature changes and routine vaccination can cause severe generalized blistering. 16,21 Therefore, patients are likely to suffer severe reactions in response to MC triggers ubiquitous in daily life unless they are educated regarding conscious avoidance of MC triggers.…”

Section: Discussionmentioning

confidence: 99%

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis

Otani

Carroll

Yager

et al. 2018

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bankova et al . presented the description of a five-month-old boy with DCM, in whom the generalised bullous eruption was observed 24 hours after routine vaccination against seven pathogens – Haemophilus influenzae , protein conjugated pneumococcal vaccine, poliomyelitis, diphtheria, pertussis, tetanus, and rotavirus [27]. The first signs of the disease appeared 12 hours after vaccination, starting with colicky pain and a day later continuing with blisters on the back, lower abdomen, and upper arms.…”

Section: Discussionmentioning

confidence: 99%

Transient hypogammaglobulinaemia of infants in children with mastocytosis – strengthened indications for vaccinations

Renke¹,

Lange²,

Dawicka³

et al. 2016

cejoi

View full text Add to dashboard Cite

Mastocytosis is a disease caused by the accumulation of mast cells (MC) in the skin and/or in other tissues. Both the cutaneous form of the disease (CM) predominating in children and the systemic form (SM) typical for adults are associated with the occurrence of MC mediator-related symptoms. The release of mediators can be induced by physical stimuli and/or specific triggering factors. The routine vaccination program performed in the majority of children in infancy can be considered as an additional factor provoking exacerbation of CM. Conscious of the important role of MC in the innate immunity, we have analysed retrospective data concerning the levels of immunoglobulins, an adaptive factor, in a group of 74 infants and toddlers with CM. The values corresponding to transient hypogammaglobulinaemia of infants (THI) were found in 8 (10.81%) of cases. Classification of the antibody deficiency was done according to the working definitions for clinical diagnosis of primary immunodeficiency of the European Society of Immunodeficiencies (ESID) Registry – version May 11, 2015. Following the retrospective data, the final diagnosis of THI cannot be made due to the young age of the study group. The percentage may significantly exceed the published incidence of THI, i.e. about 0.11%. The results of our study may indicate, importantly, a higher incidence of THI in childhood-onset mastocytosis than in the general paediatric population and strengthen indications for vaccinations. In conclusion, we suggest that THI may be considered as a new aspect of paediatric mastocytosis that requires further investigation.

show abstract

“… a Frequency of mast cell (MC) mediator-related symptoms of 2% in pediatric mastocytosis and 14% in adult mastocytosis 83 b Frequency of MC mediator-related symptoms and anaphylaxis of 2% and 0.4% in adult mastocytosis, respectively 84 ; 4% of MC mediator-related symptoms and 0–2% of anaphylaxis in pediatric mastocytosis 84– 86 c Prophylactic anti-mediator therapy is recommended in all cases 87 d Infrequent, based on one case report (Javed Sheik, Beth Israel Hospital, Harvard Medical School, personal communication, September 2002) e Infrequent, based on case report 88 f Infrequent, based on case reports 89, 90 GI, gastrointestinal; IgE, immunoglobulin E; NSAID, non-steroidal anti-inflammatory drug. Adapted with permission from Ergon 91 .…”

Section: Clinical Features Of Patients With Primary Mast Cell Activatmentioning

confidence: 99%

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

et al. 2016

View full text Add to dashboard Cite

Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.

show abstract

Generalized Bullous Eruption after Routine Vaccination in a Child with Diffuse Cutaneous Mastocytosis

Cited by 33 publications

References 7 publications

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis

Transient hypogammaglobulinaemia of infants in children with mastocytosis – strengthened indications for vaccinations

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

Contact Info

Product

Resources

About